A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-01 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
"Precautionary measures in radiation protection use the generally accepted model that the risk of lung cancer increases uniformly (linearly) with radon concentration. This means that an increased risk of lung cancer does not only occur above a certain value, but that a guideline or limit value only adjusts the magnitude of the risk in a meaningful way to other existing risks. Achieving a guideline or limit therefore means taking a risk that is still (socially) acceptable. It therefore makes perfect sense to take simple measures to reduce radon levels, even if they are below the guideline values." In Austria, the Radon Protection Ordinance in its version of September 10, 2021 is currently in force, which also defines the radon protection areas and radon precautionary areas.
The thomson (symbol: Th) is a unit that has appeared infrequently in scientific literature relating to the field of mass spectrometry as a unit of mass-to-charge ratio. The unit was proposed by R. Graham Cooks and Alan L. Rockwood naming it in honour of J. J. Thomson, who measured the mass-to-charge ratio of electrons and ions.
==== Kazakhstan ==== Institute of World Economics and Politics (IWEP) at the Foundation of the First President of the Republic of Kazakhstan was created in 2003. IWEP activities aimed at research problems of the world economy, international relations, geopolitics, security, integration and Eurasia, as well as the study of the First President of the Republic of Kazakhstan and its contribution to the establishment and strengthening of Kazakhstan as an independent state, the development of international cooperation and the promotion of peace and stability. The Kazakhstan Institute for Strategic Studies under the President of the RK (KazISS) was established by the Decree of the President of RK on 16 June 1993. Since its foundation the main mission of the Kazakhstan Institute for Strategic Studies under the President of the Republic of Kazakhstan, as a national think tank, is to maintain analytical and research support for the President of Kazakhstan.
Sources: en.wikipedia.org
Indoor air quality can be addressed, achieved or maintained during the design of new buildings or as mitigating measures in existing buildings. A hierarchy of measures has been proposed by the Institute of Air Quality Management. It emphasizes removing pollutant sources, reducing emissions from any remaining sources, disrupting pathways between sources and the people exposed, protecting people from exposure to pollutants, and removing people from areas with poor air quality. A report assisted by the Institute for Occupational Safety and Health of the German Social Accident Insurance can support in the systematic investigation of individual health problems arising at indoor workplaces, and in the identification of practical solutions.
An identical band was found doing the reverse order of the detection; meaning Myc antibody was immunoprecipitated then followed by blotting with the HA antibody. So, the method had proven to work that photo-Met could cross-link proteins, but the physiological implications of this cross-linking has yet to be determined.
=== Setting and characters === Whereas Half-Life was set in a single location, the Black Mesa research facility, Valve wanted "a much more epic and global feel" for the sequel. One concept had the player teleporting between planets, which was discarded as it would make continuity between levels difficult. At the suggestion of the art director, Viktor Antonov, who was Bulgarian, the team settled on a city in an Eastern European location. In this early concept, players would start at the boarding of the Borealis, an icebreaker bound for the city. Nova Prospekt was conceived as a small rail depot built on an old prison in the wasteland and grew from a stopping-off point to the destination itself. After observing how players had connected to minor characters in Half-Life, the team developed the characterization, with more detailed character models and realistic animation. The animator Ken Birdwell studied the work of the psychologist Paul Ekman, who had researched how facial muscles express emotion. The writer Marc Laidlaw created family relationships between the characters, saying that it was a "basic dramatic unit everyone understands" but rarely used in games. The voice cast included Louis Gossett Jr., Robert Guillaume and Robert Culp.
Sources: en.wikipedia.org
In 1912, Frederick Gowland Hopkins demonstrated that unknown accessory factors found in milk, other than carbohydrates, proteins, and fats were necessary for growth in rats. Hopkins received a Nobel Prize for this discovery in 1929. By 1913, one of these substances was independently discovered by Elmer McCollum and Marguerite Davis at the University of Wisconsin–Madison, and Lafayette Mendel and Thomas Burr Osborne at Yale University. McCollum and Davis ultimately received credit because they submitted their paper three weeks before Mendel and Osborne. Both papers appeared in the same issue of the Journal of Biological Chemistry in 1913. The "accessory factors" were termed "fat soluble" in 1918, and later "vitamin A" in 1920. In 1919, Harry Steenbock (University of Wisconsin–Madison) proposed a relationship between yellow plant pigments (β-carotene) and vitamin A. In 1931, Swiss chemist Paul Karrer described the chemical structure of vitamin A. Retinoic acid and retinol were first synthesized in 1946 and 1947 by two Dutch chemists, David Adriaan van Dorp and Jozef Ferdinand Arens.
During the first phase, from 1804 to 1806, it was a conservative reaction to new abuses by the Janissaries and Dahis, after they killed Hadji Mustafa Pasha (vizier of the Sanjak of Smederevo). He had created a militia of Serbs fighting the Janissaries that were expelled from Belgrade and had found refuge with Osman Pazvantoğlu, governor of the Sanjak of Vidin (in present-day Bulgaria), who pursued his own policy and sought independence, which brought him into conflict with the Serbs and later with the Sublime Porte. The Janissaries managed to return to Belgrade and realized the Slaughter of the Knezes. Thus, the Serbs appealed to Sultan Selim III for assistance against the Dahis, who had since rejected the authority of the Porte. Also, Karađorđe negotiated with the Austrian captain Sajtinski. At this meeting, he expressed the wish of the Serbian people that the Austrian Empire receive them as a kingdom under its protection like in the past, as occupation of 1788–1791 was still a fresh memory. However, the Austrian authorities, due to difficulties with Napoleon and because they wanted to maintain their neutrality in order to be correct with the Porte, could not accept his offers. So, the Serbs were forced to ask for the protection of the Russians, and therefore, on 3 May 1804, the Serb leaders sent a letter to the Russian envoy in Constantinople, in which they spoke of the problems and wishes of the Serbian people, but they also stressed that they would continue to be loyal to the Sultan.
=== Inequalities === People living with AD and other forms of dementia and their unpaid carers might face inequalities in access to and the quality of care and support services. These inequalities can depend on various factors, including socio-economic background, housing situation, education level, gender, and race. People might have differences in how easily they can access AD services based on where they live. On a global level, people in low-and middle-income countries have fewer available facilities and services, and have greater difficulties accessing these than people living in high-income countries. As a result of AD and other forms of dementia being less recognised and treated in the healthcare systems of these countries, the level of awareness of AD as something caused by disease is relatively lower. At the same time, the local socio-cultural understandings of aging, senility, and eldercare may have larger effects on care provision and the reception of medical services. On a national level, people with AD might have unequal access to care based on where they live. This can manifest on a regional level, with people in rural areas facing more difficulties than those in urban areas. Inequalities can also affect smaller local units as well, for example people living in the same city might receive different or less frequent care based on their postcodes or the street they live in. Inequalities also affect people with AD from ethnic minority groups.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.